scholarly journals Resilience as a Mediator of the Association Between Perceived Stigma and Quality of Life Among People With Inflammatory Bowel Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Dan Luo ◽  
Meijing Zhou ◽  
Lifu Sun ◽  
Zheng Lin ◽  
Qiugui Bian ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Perceived Stigma ◽  
Improvement Program ◽  
Cross Sectional ◽  
Inflammatory Bowel ◽  
The Relationship

Background: Improving Quality of Life (QOL) is an essential objective in the management of inflammatory bowel disease. An accumulating body of research has been conducted to explore the association between perceived stigma and QOL among patients with chronic illness. Still, underlying mechanisms behind this pathway have not been thoroughly examined.Objective: To investigate (a) the effect of perceived stigma on QOL among patients with inflammatory bowel disease; and (b) the mediating role of resilience in the association between perceived stigma and QOL.Methods: This cross-sectional study included a convenient sample of patients diagnosed with inflammatory bowel disease from four tertiary hospitals in Jiangsu Province, China. Patients completed the Perceived Stigma Scale in Inflammatory Bowel Disease (PSS-IBD), the Resilience Scale for Patients with Inflammatory Bowel Disease (RS-IBD), and the Inflammatory Bowel Disease Questionnaire (IBDQ). A bootstrapping analysis was implemented using the SPSS macro PROCESS.Results: A total of 311 patients with Cohn's disease and ulcerative colitis participated in this study, and 57.6% were men. The mean disease duration was 3.51 ± 1.04 years. Approximately 40% of the sample exceeded the criterion score for moderate stigma. Patients who perceived moderate or severe stigma reported lower QOL compared with those with mild stigma. After controlling for sociodemographic and clinical variables, we observed that perceived stigma was negatively associated with resilience. Moreover, resilience was found to mediate the relationship between perceived stigma and all aspects of QOL.Conclusions: These findings suggested that QOL of patients with inflammatory bowel disease was associated with perceived stigma and resilience and identified the mediating effects of resilience in the relationship between perceived stigma and QOL. Furthermore, this suggests that integrating intervention techniques to target resilience into the QOL improvement program of individuals with perceived stigma is possible.

scholarly journals Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

2021 ◽  
Vol 14 ◽  
pp. 175628482110561
Author(s):  
Carlos Taxonera ◽  
María Pilar Martínez-Montiel ◽  
Manuel Barreiro-de-Acosta ◽  
Isabel Vera ◽  
Rufo Lorente ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Single Dose ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Global Satisfaction ◽  
Related Quality ◽  
Inflammatory Bowel

Background: A recently registered device containing 80 mg of adalimumab (ADA) allows an alternative dose escalation regimen with ADA 80 mg every other week (EOW) given as a single subcutaneous injection instead of 40 mg every week. The ADASCAL study evaluated the preferences and satisfaction of inflammatory bowel disease (IBD) patients after switching their ADA regimen from 40 mg weekly to 80 mg EOW given with a single-dose pen. Methods: In this multicentre cross-sectional study, patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW completed the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), a four-item questionnaire [a Likert-type 5-point scale for preferences, two closed questions for convenience and a 100-point visual analogue scale (VAS) to assess which escalated ADA regimen patients would prefer to continue] and two Health-Related Quality of Life (HRQoL) questionnaires: the generic European Quality of Life–5 Dimensions (EQ-5D) and disease-specific Spanish version of the Inflammatory Bowel Disease Questionnaire (SIBDQ-9). Results: In total, 77 patients (64 Crohn’s disease and 13 ulcerative colitis) were included. The TSQM score showed a notably high global satisfaction [83.4, standard deviation (SD) = 14.1] of patients with ADA 80 mg EOW given with a single-dose pen, with high TSQM scores for individual components: effectiveness (77.6, SD = 16.9), convenience (83.7, SD = 14.5) and side effects (86.1, SD = 23.4). Most of the patients (74%) preferred the ADA EOW regimen (59.7% had strong preference, 14.3% slight preference). ADA EOW interferes less with daily activity (59.7%) and with travel plans (81.8%). Most patients (77%) would prefer to continue with ADA EOW (mean VAS score of 84.7, SD = 24.1, where 100 indicates a preference for ADA EOW). Patients reported high HRQoL scores on both the EQ-5D (72.3, SD = 20.1) and SIBDQ-9 (75.1, SD = 14.7). Conclusion: IBD patients in whom the ADA regimen was changed from 40 mg weekly to 80 mg EOW reported a higher preference for the EOW regimen and therefore most decided to continue with a single self-injection EOW.

scholarly journals Quality of Life in Cohabitants of Patients Suffering Inflammatory Bowel Disease: A Cross-Sectional Study

2021 ◽  
Vol 19 (1) ◽  
pp. 115
Author(s):  
Manuel López-Vico ◽  
Antonio D. Sánchez-Capilla ◽  
Eduardo Redondo-Cerezo
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Chronic Inflammatory Condition ◽  
Inflammatory Bowel

(1) Background: Inflammatory bowel disease (IBD) is a chronic inflammatory condition with a significant impact on patients’ general health perception. No studies have considered consequences of IBD on cohabitants. (2) Aims: The aims of this study were to address the influence of IBD on cohabitants’ quality of life (QoL) and the factors potentially conditioning this impact. (3) Methods: We conducted a cross-sectional study in which IBD patients and their cohabitants were invited to participate. Validated questionnaires were used to measure QoL in patients and cohabitants. Main clinical and sociodemographic variables were collected. (4) Results: A total of 56 patients and 82 cohabitants with significant QoL impairment were included. A direct association was found between Inflammatory Bowel Disease Questionnaire (IBDQ32) score in patients and the Household Members Quality of Life—Inflammatory Bowel Disease (HHMQoL-IBD). IBDQ32 was related to the number of flares in the last 12 months, number of hospital admissions and Mayo Score. (5) Conclusions: HHMQoL-IBD score was related to patients IBDQ32 score and the presence of extraintestinal disease. We identified CRP, a marker of disease activity, as a factor related to cohabitants’ quality of life, pointing to a direct relationship of patients’ disease activity and their cohabitants’ quality of life.

scholarly journals A243 FACTORS ASSOCIATED WITH POOR QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION: A CROSS-SECTIONAL STUDY

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. 120-121
Author(s):  
A Nazarian ◽  
K Bishay ◽  
R Gholami ◽  
M A Scaffidi ◽  
R Khan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Remission ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Inflammatory Bowel ◽  
Anxiety Depression

Abstract Background Inflammatory bowel disease (IBD) is associated with a substantial burden on quality of life (QoL). Functional gastrointestinal disorders such as irritable bowel syndrome (IBS) as well as depression and anxiety are more common in patients with IBD as compared with the general population. Although poorer QoL is correlated with IBS, depression and anxiety in individuals with IBD at times of IBD diagnosis and disease activity, it is unclear what, if any, impact these may have on overall quality of life at times of disease remission. Aims We aimed to identify factors associated with poor QoL among Canadian patients with IBD in clinical remission. Methods We conducted a prospective, cross-sectional study to determine whether fatigue, depression, anxiety and IBS were associated with lower QoL in patients with IBD in clinical remission. We enrolled patients at a single academic tertiary care center with inactive IBD. All eligible patients completed a series of questionnaires that included questions on demographics, disease activity, anxiety, depression, and the presence of irritable bowel syndrome (IBS) symptoms. Stool samples for fecal calprotectin (FC) were also collected to assess for subclinical inflammation. The primary outcome measure was QoL assessed by the short inflammatory bowel disease questionnaire (SIBDQ), with planned subgroup comparisons for fatigue, anxiety, depression and IBS symptoms. Results Ninety-three patients were eligible for inclusion in this study. The median SIBDQ scores were lower in patients with anxiety (P<0.001), depression (P=0.004), IBS symptoms (P<0.001), and fatigue (P=0.018). Conclusions In this cross-sectional study, we found that anxiety, depression, fatigue, and IBS-like symptoms were all independently associated with lower QoL among patients with inactive IBD. Importantly, subclinical inflammation as defined by a positive fecal calprotectin in the absence of clinical symptoms did not have an adverse effect on QoL. The findings of this study suggest that patients with IBD would likely benefit from screening for depression, anxiety, fatigue and IBS. Further research is warranted to determine if targeted treatment of these conditions, specifically in patients with quiescent IBD would lead to improved outcomes. Funding Agencies None

scholarly journals Quality of life in inflammatory bowel disease patients: A cross-sectional study

2017 ◽  
Vol 22 (1) ◽  
pp. 104 ◽  
Author(s):  
SadeghBaradaran Mahdavi ◽  
Farzaneh Habibi ◽  
MohammadEmadoddin Habibi ◽  
Ali Gharavinia ◽  
MohammadJavad Akbarpour ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Inflammatory Bowel

scholarly journals P467 Perception Gap between Patients with Inflammatory Bowel Disease (IBD) and Physicians in China: A Cross-sectional Study

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S457-S458
Author(s):  
J Liang ◽  
Q Cao ◽  
M Chen ◽  
K Wu
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Disease ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Treatment Results ◽  
Cross Sectional ◽  
Bothersome Symptom ◽  
Inflammatory Bowel ◽  
Repeated Medication

Abstract Background The aim of the study was to assess the perception of inflammatory bowel disease (IBD) among Chinese patients and physicians. Methods Data in this cross-sectional study was collected from 6/2020 to 8/2020, which covered 24 provinces/cities in China and based on two surveys that was designed for collecting information from patients with Crohn’s disease (CD)/ulcerative colitis (UC) and the physicians. Results Surveys were completed by 1058 patients (601 CD and 457 UC patients) and 351 physicians (181 treating CD and 170 treating UC). For the control of disease symptoms over the past 12 months, physicians believed that 65.19% and 57.65% of CD and UC patients, respectively, were managed without affecting their quality of life. Meanwhile, 56.07% and 49.46% of CD and UC patients, respectively, reported that disease control did not affect their quality of life. Physicians estimated that 87.85% of CD and 88.24% of UC patients were satisfied with treatment results. And 86.36% of CD and 79.43% of UC patients were satisfied with the current medications. Physicians prescribed biologics for 69.52% of IBD patients, and 48.3% of IBD patients actually used them. Repeated medication (30.95%), diarrhea (27.95%) and abdominal pain (25.29%) were most frequently ranked as most bothersome symptoms by CD patients. For physicians, abdominal pain (42.54%) was the most bothersome symptoms, followed by repeated medication (23.76%) and diarrhea (17.13%). Regarding UC symptoms, 51.18% of physicians believed that bloody stool was the most bothersome symptom for patients, and 41.58% of patients held this view. The sense of urgency was concerned as one bothersome symptom by 19.69% patients, while only 4.12% of physicians held the same views (Fig 1). Regarding the efficacy evaluation, in view of the CD physicians, 42.5% of CD patients were believed achieving completely or mostly controlled, while from the patients’ perception, only 32.6% of CD patients agreed. Similarly, the proportion of UC patients who was believed by physicians that achieving completely or mostly controlled (40.0%) was also higher than that of UC patients who believed by themselves (Fig 2). Conclusion Most of the IBD patients and physicians were satisfied with the treatment results and the current medications. The disease control expectation of the patients was slightly more than that of the physicians. Further studies are needed to explore factors that associated with the treatment expectation of the patients.

Sign in / Sign up

Export Citation Format

Share Document